Last reviewed · How we verify

Azienda Ospedaliera di Perugia — Portfolio Competitive Intelligence Brief

Azienda Ospedaliera di Perugia pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Aspirin plus clopidogrel Aspirin plus clopidogrel marketed
Placebo, Palonosetron, Dexamethasone Placebo, Palonosetron, Dexamethasone phase 3 5-HT3 receptor antagonist + corticosteroid combination 5-HT3 receptor (palonosetron); glucocorticoid receptor (dexamethasone) Oncology (supportive care)

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Government Medical College, Haldwani · 1 shared drug class
  2. Guangxi Medical University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Azienda Ospedaliera di Perugia:

Cite this brief

Drug Landscape (2026). Azienda Ospedaliera di Perugia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-ospedaliera-di-perugia. Accessed 2026-05-17.

Related